I hope phase 3&4 trials are impressed with haste at minimum number of patients 300+ because of the excellent safety profile, to get FDA to approve quicker and help patients in the process,its only flu virus after all, no engineering etc,with terrific cancer fighting properties,
Viralytics already have established dose rates, delivery options, safety, compatibility, lives being lost waiting... sigh
